Amicus Therapeutics (FOLD) Competitors $7.61 +0.01 (+0.13%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.62 +0.01 (+0.13%) As of 08/22/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD vs. EXAS, MDGL, HALO, RGEN, IONS, ALKS, LGND, BCRX, CLDX, and NVAXShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Repligen (RGEN), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), and Novavax (NVAX). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Its Competitors Exact Sciences Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals Celldex Therapeutics Novavax Amicus Therapeutics (NASDAQ:FOLD) and Exact Sciences (NASDAQ:EXAS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Do analysts rate FOLD or EXAS? Amicus Therapeutics currently has a consensus price target of $16.22, suggesting a potential upside of 113.17%. Exact Sciences has a consensus price target of $67.43, suggesting a potential upside of 42.04%. Given Amicus Therapeutics' higher possible upside, research analysts clearly believe Amicus Therapeutics is more favorable than Exact Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Exact Sciences 0 Sell rating(s) 3 Hold rating(s) 20 Buy rating(s) 1 Strong Buy rating(s) 2.92 Which has higher earnings and valuation, FOLD or EXAS? Amicus Therapeutics has higher earnings, but lower revenue than Exact Sciences. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$571.16M4.11-$56.11M-$0.12-63.42Exact Sciences$2.76B3.26-$1.03B-$5.43-8.74 Is FOLD or EXAS more profitable? Amicus Therapeutics has a net margin of -6.67% compared to Exact Sciences' net margin of -34.19%. Exact Sciences' return on equity of -1.75% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-6.67% -5.07% -1.23% Exact Sciences -34.19%-1.75%-0.76% Which has more risk and volatility, FOLD or EXAS? Amicus Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Do institutionals and insiders hold more shares of FOLD or EXAS? 88.8% of Exact Sciences shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 1.2% of Exact Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor FOLD or EXAS? In the previous week, Exact Sciences had 3 more articles in the media than Amicus Therapeutics. MarketBeat recorded 14 mentions for Exact Sciences and 11 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.40 beat Exact Sciences' score of 1.02 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 9 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryExact Sciences beats Amicus Therapeutics on 10 of the 17 factors compared between the two stocks. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.35B$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-63.4121.0031.3626.05Price / Sales4.11209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book11.538.129.536.60Net Income-$56.11M-$54.72M$3.26B$265.65M7 Day Performance2.84%2.62%2.14%2.00%1 Month Performance21.18%3.25%3.22%0.46%1 Year Performance-35.29%10.82%30.18%18.88% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics4.3514 of 5 stars$7.61+0.1%$16.22+113.2%-35.3%$2.35B$571.16M-63.41480News CoveragePositive NewsEXASExact Sciences4.9291 of 5 stars$45.09-1.1%$67.43+49.5%-20.5%$8.63B$2.76B-8.307,000News CoveragePositive NewsMDGLMadrigal Pharmaceuticals3.5231 of 5 stars$391.43+5.8%$439.71+12.3%+64.1%$8.21B$180.13M-30.4690News CoverageAnalyst ForecastInsider TradeAnalyst RevisionHALOHalozyme Therapeutics4.6963 of 5 stars$68.96+2.5%$67.11-2.7%+14.5%$7.87B$1.18B15.78390News CoveragePositive NewsRGENRepligen4.8567 of 5 stars$124.08-0.2%$169.45+36.6%-15.0%$7.00B$634.44M-496.301,778News CoveragePositive NewsIONSIonis Pharmaceuticals4.6381 of 5 stars$43.43-0.8%$59.38+36.7%-9.0%$6.98B$705M-23.601,069Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionALKSAlkermes4.7395 of 5 stars$28.11-3.2%$41.08+46.2%+6.4%$4.80B$1.56B13.511,800Trending NewsAnalyst RevisionLGNDLigand Pharmaceuticals4.1149 of 5 stars$153.26+1.4%$157.00+2.4%+53.2%$2.96B$167.13M-38.3280News CoveragePositive NewsShort Interest ↓BCRXBioCryst Pharmaceuticals4.2021 of 5 stars$8.38+0.1%$16.70+99.3%+5.7%$1.76B$450.71M-46.55530Positive NewsCLDXCelldex Therapeutics1.6055 of 5 stars$24.48-4.0%$51.75+111.4%-39.6%$1.69B$7.02M-8.13150News CoverageAnalyst ForecastNVAXNovavax4.6172 of 5 stars$9.71+1.4%$15.86+63.3%-34.6%$1.56B$682.16M4.261,990News CoverageAnalyst Forecast Related Companies and Tools Related Companies EXAS Alternatives MDGL Alternatives HALO Alternatives RGEN Alternatives IONS Alternatives ALKS Alternatives LGND Alternatives BCRX Alternatives CLDX Alternatives NVAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FOLD) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access